Lastly, to confirm the data on gene expression with the phenotypic characterization of CAR.CD19-T cells, the CAR.CD19-T cell activation phenotype was tested upon challenge with lymphoma cells (E:T ratio of 1:1), in the presence or absence of emapalumab. This evidence concerns the gene CD19 and lymphoma.